Oleylphosphocholine

The promise of organic ionic plastic crystals (OIPCs) for development of a novel type of gas separation membrane with competitive gas selectivity for CO2/N2 was recently demonstrated. This work aimed to design more selective membranes by investigating a different type of OIPC and a new membrane preparation method. Two different OIPCs were solvent‐cast or co‐cast with poly(vinylidene difluoride) (PVDF), and their gas transport properties were compared. The first OIPC, methyl(diethyl)isobutylphosphonium hexafluorophosphate ([P122i4][PF6]), was previously studied using the co‐cast method, and this was used as a benchmark. The second, N‐methyl‐N‐ethylpyrrolidinium bis(fluorosulfonyl)imide ([C2mpyr][FSI]), was investigated for the first time for gas separation applications, achieving high selectivities (α >40). The thermophysical properties of the composites indicated that the co‐casting method is a good way to fabricate solid, mechanically stable and durable membranes. Additionally, the enhanced molecular interactions indicated in OIPC/PVDF co‐cast composites point to a new approach for synthesis of other highly selective OIPC‐based membranes.

In preclinical studies, oral azacitidine (CC-486), a hypomethylating agent, has been shown to have a direct anti-MM effect and in vitro anti-MM synergism when combined with lenalidomide (LEN). We present a phase 1b, single center, 3 × 3 dose escalation study with planned expansion at maximum tolerated dose (MTD), which assessed the safety and efficacy of combining CC-486 with LEN (25 mg d1-21/28) and dexamethasone (DEX) (40 mg weekly) in patients with relapsed/refractory MM who had previously failed LEN. Twenty-four patients were enrolled. The MTD of CC-486 was 150 mg d1-21; recommended expansion dose was 100 mg d1-21. Adverse events were predictable and manageable. ORR was 37.5%; clinical benefit rate was 50%. Median OS was 10.3 m; median PFS was 2.6 m. Correlative proteomics demonstrated that higher MM tumor cell cereblon expression (pretreatment, C1D5) was associated with superior PFS/OS. CC-486, LEN and DEX produced meaningful clinical responses in heavily treated LEN refractory MM patients. Proteomics may have utility in predicting clinical outcomes.